NCT04381650

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Completed Phase 1, PHASE2 Results posted Last updated 10 December 2025

What this trial tests

Phase 1, PHASE2 trial testing TAK-981 in Advanced or Metastatic Solid Tumors in 161 participants. Completed in 29 October 2024.

Timeline

17 August 2020

Primary endpoint
29 October 2024

29 October 2024

Quick facts

Lead sponsor	Takeda
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	161
Start date	17 August 2020
Primary completion	29 October 2024
Estimated completion	29 October 2024
Sites	52 locations across Japan, Poland, Lithuania, Switzerland, China, Croatia, United States, Brazil

Drugs / interventions tested

• TAK-981 — full drug profile →
• Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

• Advanced or Metastatic Solid Tumors — all drugs for Advanced or Metastatic Solid Tumors →

Sponsor

Takeda — full company profile →

Who can join

18 and older, any sex, with Advanced or Metastatic Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Phase 1: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) Primary · Up to approximately 24 months

An adverse event (AE) is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. A TEAE is defined as an AE that occurs after administration of first dose of study drug and through 30 days after last dose of study drug or until start of subsequent antineoplastic therapy. AEs were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0 except cytokine release syndrome (CRS), which was grad

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	3
Dose Escalation: TAK-981 60 mg	6
Dose Escalation: TAK-981 90 mg	33
Dose Escalation: TAK-981 120 mg	19

Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) Primary · Up to Cycle 1 (each cycle was of 21 days)

DLTs were evaluated according to NCI CTCAE Version 5.0 except CRS, which was graded according to ASTCT Consensus Grading for CRS.

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	0
Dose Escalation: TAK-981 60 mg	0
Dose Escalation: TAK-981 90 mg	2
Dose Escalation: TAK-981 120 mg	1

Phase 1: Number of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs) Primary · Up to approximately 24 months

AE means any untoward medical occurrence in a participant administered a pharmaceutical product. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product whether or not it is related to the medicinal product. A TEAE was defined as an adverse event which occurred on or after the first dose of study drug and no more than 30 days after the last dose of study drug. A severity grade was evaluated as per the NCI CTCAE Version 5.0, except for CRS, which was assessed by ASTCT Consensus Grading for CRS.

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	0
Dose Escalation: TAK-981 60 mg	2
Dose Escalation: TAK-981 90 mg	20
Dose Escalation: TAK-981 120 mg	15

Phase 1: Number of Participants With One or More Serious Adverse Events (SAEs) Primary · Up to approximately 24 months

An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	0
Dose Escalation: TAK-981 60 mg	3
Dose Escalation: TAK-981 90 mg	17
Dose Escalation: TAK-981 120 mg	10

Phase 1: Number of Participants With One or More TEAEs Leading to Dose Modifications and Treatment Discontinuation Primary · Up to approximately 24 months

An AE is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. A TEAE is defined as an AE that occurs after administration of first dose of study drug and through 30 days after last dose of study drug or until start of subsequent antineoplastic therapy.

TEAE Resulting in Dose Modifications of TAK-981

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	0
Dose Escalation: TAK-981 60 mg	3
Dose Escalation: TAK-981 90 mg	22
Dose Escalation: TAK-981 120 mg	11

TEAE Resulting in Dose Modifications of Pembrolizumab

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	0
Dose Escalation: TAK-981 60 mg	3
Dose Escalation: TAK-981 90 mg	15
Dose Escalation: TAK-981 120 mg	4

TEAE Resulting in Drug Discontinuation of TAK-981

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	0
Dose Escalation: TAK-981 60 mg	1
Dose Escalation: TAK-981 90 mg	3
Dose Escalation: TAK-981 120 mg	2

TEAE Resulting in Drug Discontinuation of Pembrolizumab

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	0
Dose Escalation: TAK-981 60 mg	1
Dose Escalation: TAK-981 90 mg	4
Dose Escalation: TAK-981 120 mg	1

Phase 1: Number of Participants With Clinically Significant Laboratory Values Primary · Up to approximately 24 months

Laboratory parameters included clinical chemistry, hematology, and urinalysis. Participants with at least 1 Grade 3 or 4 Lab Abnormalities were reported.

Hematology

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	1
Dose Escalation: TAK-981 60 mg	3
Dose Escalation: TAK-981 90 mg	7
Dose Escalation: TAK-981 120 mg	6

Serum Chemistry

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	1
Dose Escalation: TAK-981 60 mg	1
Dose Escalation: TAK-981 90 mg	7
Dose Escalation: TAK-981 120 mg	5

Coagulation

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	0
Dose Escalation: TAK-981 60 mg	0
Dose Escalation: TAK-981 90 mg	0
Dose Escalation: TAK-981 120 mg	1

Phase 2: Overall Response Rate (ORR) as Assessed by the Investigator According to RECIST, Version 1.1 Primary · Up to approximately 25 months

ORR is defined as the percentage of participants who achieve Complete Response (CR) and Partial Response (PR) (determined by the investigator) during the study according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

Group	Value	95% CI
Dose Expansion: Cohort A: Non-squamous NSCLC TAK-981 90 mg	20	2.52 – 55.61
Dose Expansion: Cohort A: Non-squamous NSCLC TAK-981 120 mg	0	0.00 – 36.94
Dose Expansion: Cohort B: Cervical Cancer TAK-981 90 mg	30	11.89 – 54.28
Dose Expansion: Cohort C: MSS-CRC TAK-981 90 mg	0	0.00 – 33.63
Dose Expansion: Cohort D: Cutaneous Melanoma TAK-981 90 mg	25	10.69 – 44.87
Dose Expansion: Cohort E: Squamous NSCLC TAK-981 90 mg	7.7	0.19 – 36.03
Dose Expansion: Cohort F: CPI Refractory Squamous and Non-squamous NSCLC TAK-981 90 mg	0	0.00 – 60.24

Phase 1: Cmax: Maximum Observed Plasma Concentration for TAK-981 Secondary · Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours)

Cycle 1 Day 1

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	335	± 282
Dose Escalation: TAK-981 60 mg	728	± 396
Dose Escalation: TAK-981 90 mg	888	± 423
Dose Escalation: TAK-981 120 mg	1290	± 571

Cycle 1 Day 8

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	280	± 167
Dose Escalation: TAK-981 60 mg	448	± 206
Dose Escalation: TAK-981 90 mg	780	± 524
Dose Escalation: TAK-981 120 mg	1270	± 770

Phase 1: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-981 Secondary · Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours)

Cycle 1 Day 1

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	1.22	1.20 – 1.23
Dose Escalation: TAK-981 60 mg	1.27	1.00 – 1.47
Dose Escalation: TAK-981 90 mg	1.17	1.00 – 1.88
Dose Escalation: TAK-981 120 mg	1.20	1.00 – 1.72

Cycle 1 Day 8

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	1.18	1.17 – 1.25
Dose Escalation: TAK-981 60 mg	1.41	1.00 – 1.70
Dose Escalation: TAK-981 90 mg	1.22	1.00 – 3.10
Dose Escalation: TAK-981 120 mg	1.28	0.98 – 1.50

Phase 1: AUC0-t: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for TAK-981 Secondary · Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours)

Cycle 1 Day 1

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	880	± 427
Dose Escalation: TAK-981 60 mg	1370	± 517
Dose Escalation: TAK-981 90 mg	1950	± 735
Dose Escalation: TAK-981 120 mg	2580	± 949

Cycle 1 Day 8

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	814	± 290
Dose Escalation: TAK-981 60 mg	976	± 232
Dose Escalation: TAK-981 90 mg	1780	± 908
Dose Escalation: TAK-981 120 mg	2640	± 1260

Phase 1: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-981 Secondary · Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours)

Cycle 1 Day 1

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	909	± 432
Dose Escalation: TAK-981 60 mg	1400	± 530
Dose Escalation: TAK-981 90 mg	2020	± 760
Dose Escalation: TAK-981 120 mg	2660	± 1020

Cycle 1 Day 8

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	845	± 292
Dose Escalation: TAK-981 60 mg	1010	± 233
Dose Escalation: TAK-981 90 mg	1830	± 942
Dose Escalation: TAK-981 120 mg	2750	± 1320

Phase 1: t1/2z: Terminal Disposition Phase Half-life for TAK-981 Secondary · Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours)

Cycle 1 Day 1

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	5.88	5.82 – 6.16
Dose Escalation: TAK-981 60 mg	5.58	5.04 – 6.03
Dose Escalation: TAK-981 90 mg	5.72	3.31 – 10.43
Dose Escalation: TAK-981 120 mg	6.79	5.93 – 8.14

Cycle 1 Day 8

Group	Value	95% CI
Dose Escalation: TAK-981 40 mg	5.83	5.69 – 6.33
Dose Escalation: TAK-981 60 mg	5.68	5.22 – 6.44
Dose Escalation: TAK-981 90 mg	6.06	4.18 – 9.13
Dose Escalation: TAK-981 120 mg	6.67	5.26 – 8.08

Adverse events — posted to ClinicalTrials.gov

Time frame: Phase 1: Up to approximately 24 months, Phase 2: Up to approximately 25 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Dose Escalation: TAK-981 40 mg

Serious: 0/3 (0%)

Deaths: 2/3

Dose Escalation: TAK-981 60 mg

Serious: 3/6 (50%)

Deaths: 2/6

Dose Escalation: TAK-981 90 mg

Serious: 17/33 (52%)

Deaths: 8/33

Dose Escalation: TAK-981 120 mg

Serious: 10/19 (53%)

Deaths: 4/19

Dose Expansion: Cohort A: Non-squamous NSCLC TAK-981 90 mg

Serious: 3/14 (21%)

Deaths: 2/14

Dose Expansion: Cohort A: Non-squamous NSCLC TAK-981 120 mg

Serious: 4/9 (44%)

Deaths: 4/9

Dose Expansion: Cohort B: Cervical Cancer TAK-981 90 mg

Serious: 11/21 (52%)

Deaths: 9/21

Dose Expansion: Cohort C: MSS-CRC TAK-981 90 mg

Serious: 4/9 (44%)

Deaths: 2/9

Dose Expansion: Cohort D: Cutaneous Melanoma TAK-981 90 mg

Serious: 14/28 (50%)

Deaths: 8/28

Dose Expansion: Cohort E: Squamous NSCLC TAK-981 90 mg

Serious: 5/15 (33%)

Deaths: 2/15

Dose Expansion: Cohort F: CPI Refractory Squamous or Non-squamous NSCLC TAK-981 90 mg

Serious: 3/4 (75%)

Deaths: 1/4

Serious adverse events (76 terms)

Reaction	System	Dose Escalation: TAK-981 4…	Dose Escalation: TAK-981 6…	Dose Escalation: TAK-981 9…	Dose Escalation: TAK-981 1…	Dose Expansion: Cohort A: …	Dose Expansion: Cohort A: …	Dose Expansion: Cohort B: …	Dose Expansion: Cohort C: …	Dose Expansion: Cohort D: …	Dose Expansion: Cohort E: …	Dose Expansion: Cohort F: …
Cytokine release syndrome	Immune system disorders	—	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Biliary obstruction	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—
Large intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Pneumonia bacterial	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Abdominal distension	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Acute myeloid leukaemia	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—	—
Adrenal insufficiency	Endocrine disorders	—	—	—	—	—	—	—	—	—	—	—
Anaphylactic shock	Immune system disorders	—	—	—	—	—	—	—	—	—	—	—
Aortic aneurysm rupture	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—
Aplasia pure red cell	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Arrhythmia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Ascites	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Atrioventricular block	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Cancer pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—	—
Cervix carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—	—
Cholangitis acute	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—
Colorectal cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—	—
Dermatomyositis	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Device related thrombosis	General disorders	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (249 terms — click to expand)

Reaction	System	Dose Escalation: TAK-981 4…	Dose Escalation: TAK-981 6…	Dose Escalation: TAK-981 9…	Dose Escalation: TAK-981 1…	Dose Expansion: Cohort A: …	Dose Expansion: Cohort A: …	Dose Expansion: Cohort B: …	Dose Expansion: Cohort C: …	Dose Expansion: Cohort D: …	Dose Expansion: Cohort E: …	Dose Expansion: Cohort F: …
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Infusion related reaction	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—	—
Vitiligo	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Platelet count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Blood lactate dehydrogenase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—
Hypothyroidism	Endocrine disorders	—	—	—	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—	—	—	—
Dermatitis acneiform	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Lymphocyte count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Malaise	General disorders	—	—	—	—	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Rash maculo-papular	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Abnormal loss of weight	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Blood creatinine increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
CD4 lymphocytes decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Cytokine release syndrome, Anaemia, Atrial fibrillation, Biliary obstruction, Large intestinal obstruction, Pneumonia, Pneumonia bacterial, Sepsis.

Data from ClinicalTrials.gov NCT04381650 adverse events section.

Sponsor's own description

TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors.

The study aims are to evaluate the safety, tolerability, and preliminary efficacy of TAK-981 in combination with pembrolizumab.

Participants will be on this combination treatment for 21-day cycles. They will continue with this treatment for up to 24 months or until participants meet any discontinuation criteria.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.
   Lightcap ES, Yu P, Grossman S, Song K, et al · · 2021 · cited 111× · PMID 34524860 · DOI 10.1126/scitranslmed.aba7791
2. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
   Kumar S, Schoonderwoerd MJA, Kroonen JS, de Graaf IJ, et al · · 2022 · cited 110× · PMID 35074907 · DOI 10.1136/gutjnl-2021-324834
3. ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes.
   Lu Z, McBrearty N, Chen J, Tomar VS, et al · · 2022 · cited 68× · PMID 36070682 · DOI 10.1016/j.cmet.2022.08.007
4. Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.
   Demel UM, Böger M, Yousefian S, Grunert C, et al · · 2022 · cited 66× · PMID 35499080 · DOI 10.1172/jci152383
5. Therapeutic Potential of Targeting the SUMO Pathway in Cancer.
   Kukkula A, Ojala VK, Mendez LM, Sistonen L, et al · · 2021 · cited 61× · PMID 34503213 · DOI 10.3390/cancers13174402
6. The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
   Nakamura A, Grossman S, Song K, Xega K, et al · · 2022 · cited 58× · PMID 35226739 · DOI 10.1182/blood.2021014267
7. Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling.
   Sharma A, Khan H, Singh TG, Grewal AK, et al · · 2021 · cited 51× · PMID 34769401 · DOI 10.3390/ijms222111971
8. Ubiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases.
   Hwang JT, Lee A, Kho C. · · 2022 · cited 49× · PMID 35563444 · DOI 10.3390/ijms23095053